Literature DB >> 19820225

Measures of response in clinical trials of systemic sclerosis: the Combined Response Index for Systemic Sclerosis (CRISS) and Outcome Measures in Pulmonary Arterial Hypertension related to Systemic Sclerosis (EPOSS).

Dinesh Khanna1, Oliver Distler, Jerome Avouac, Frank Behrens, Philip J Clements, Christopher Denton, Ivan Foeldvari, Edward Giannini, Doerte Huscher, Otylia Kowal-Bielecka, Daniel Lovell, Marco Matucci-Cerinic, Maureen Mayes, Peter A Merkel, Peter Nash, Christian F Opitz, David Pittrow, Lewis Rubin, James R Seibold, Virginia Steen, C Vibeke Strand, Peter S Tugwell, John Varga, Angela Zink, Daniel E Furst.   

Abstract

There have been steady efforts to develop a combined response index for systemic sclerosis (CRISS). A parallel and equally successful effort has been made by an Expert Panel on Outcome Measures in PAH related to Systemic Sclerosis (EPOSS) to measure effect in treatment of pulmonary arterial hypertension of systemic sclerosis (PAH-SSc). CRISS conducted a Delphi process combined with expert review to identify 11 candidate domains for inclusion in a core set of outcomes for SSc clinical trials: soluble biomarkers, cardiac, digital ulcers, gastrointestinal, global health, health related quality of life (HRQOL) and function, musculoskeletal, pulmonary, Raynaud's, renal, and skin. Tools within domains were also agreed upon. Concentrating on one aspect of disease, PAH, EPOSS also conducted a Delphi process and judged the following domains as the most appropriate for randomized controlled trials in PAH-SSc: lung vascular/pulmonary arterial pressure, cardiac function, exercise testing; severity of dyspnea, discontinuation of treatment; quality of life/activities of daily living; global state; and survival. Possible useful tools within each domain were also agreed on. Patient derived, physician derived, and objective measures of response will be included and combined with the idea that each reflects different aspects of PAH (EPOSS) and overall disease (CRISS) although this assumption may not prove true and can be separated if statistically and clinically valid to do so. In either case, prospective studies will require measurement of all domains, and tools are required and will be developed to define appropriate combined measures of response. CRISS and EPOSS are being developed through the OMERACT process. Through Delphi process and literature review significant progress has been made for both indices, and prospective data are being collected.

Entities:  

Mesh:

Year:  2009        PMID: 19820225     DOI: 10.3899/jrheum.090372

Source DB:  PubMed          Journal:  J Rheumatol        ISSN: 0315-162X            Impact factor:   4.666


  15 in total

1.  Reliability, validity and responsiveness to change of the Saint George's Respiratory Questionnaire in early diffuse cutaneous systemic sclerosis.

Authors:  Beth Wallace; Suzanne Kafaja; Daniel E Furst; Veronica J Berrocal; Peter A Merkel; James R Seibold; Maureen D Mayes; Dinesh Khanna
Journal:  Rheumatology (Oxford)       Date:  2015-02-09       Impact factor: 7.580

2.  Development of Clinical Trial Assessments for the Study of Interstitial Lung Disease in Patients who have Connective Tissue Diseases-Methodological Considerations.

Authors:  Dörte Huscher; Lesley Ann Saketkoo; David Pittrow; Dinesh Khanna
Journal:  Curr Rheumatol Rev       Date:  2010-05-01

3.  Feasibility and construct validity of PROMIS and "legacy" instruments in an academic scleroderma clinic.

Authors:  Dinesh Khanna; Paul Maranian; Nan Rothrock; David Cella; Richard Gershon; Puja P Khanna; Brennan Spiegel; Daniel E Furst; Phil J Clements; Amber Bechtel; Ron D Hays
Journal:  Value Health       Date:  2011-10-22       Impact factor: 5.725

Review 4.  Twenty-two points to consider for clinical trials in systemic sclerosis, based on EULAR standards.

Authors:  Dinesh Khanna; Daniel E Furst; Yannick Allanore; Sangmee Bae; Vijay Bodukam; Philip J Clements; Maurizio Cutolo; Laszlo Czirjak; Christopher P Denton; Oliver Distler; Ulrich A Walker; Marco Matucci-Cerinic; Ulf Müller-Ladner; James R Seibold; Manjit Singh; Alan Tyndall
Journal:  Rheumatology (Oxford)       Date:  2014-08-13       Impact factor: 7.580

Review 5.  Patient-reported outcome instruments in clinical trials of systemic sclerosis.

Authors:  John D Pauling; Joana Caetano; Corrado Campochiaro; Giacomo De Luca; Ana Maria Gheorghiu; Maria Grazia Lazzaroni; Dinesh Khanna
Journal:  J Scleroderma Relat Disord       Date:  2019-11-25

Review 6.  Update on juvenile systemic sclerosis.

Authors:  Ivan Foeldvari
Journal:  Curr Rheumatol Rep       Date:  2015-03       Impact factor: 4.592

Review 7.  Patient-reported outcomes in core domain sets for rheumatic diseases.

Authors:  Lilian H D van Tuyl; Maarten Boers
Journal:  Nat Rev Rheumatol       Date:  2015-09-01       Impact factor: 20.543

8.  The American College of Rheumatology Provisional Composite Response Index for Clinical Trials in Early Diffuse Cutaneous Systemic Sclerosis.

Authors:  Dinesh Khanna; Veronica J Berrocal; Edward H Giannini; James R Seibold; Peter A Merkel; Maureen D Mayes; Murray Baron; Philip J Clements; Virginia Steen; Shervin Assassi; Elena Schiopu; Kristine Phillips; Robert W Simms; Yannick Allanore; Christopher P Denton; Oliver Distler; Sindhu R Johnson; Marco Matucci-Cerinic; Janet E Pope; Susanna M Proudman; Jeffrey Siegel; Weng Kee Wong; Athol U Wells; Daniel E Furst
Journal:  Arthritis Care Res (Hoboken)       Date:  2016-02       Impact factor: 4.794

9.  The American College of Rheumatology Provisional Composite Response Index for Clinical Trials in Early Diffuse Cutaneous Systemic Sclerosis.

Authors:  Dinesh Khanna; Veronica J Berrocal; Edward H Giannini; James R Seibold; Peter A Merkel; Maureen D Mayes; Murray Baron; Philip J Clements; Virginia Steen; Shervin Assassi; Elena Schiopu; Kristine Phillips; Robert W Simms; Yannick Allanore; Christopher P Denton; Oliver Distler; Sindhu R Johnson; Marco Matucci-Cerinic; Janet E Pope; Susanna M Proudman; Jeffrey Siegel; Weng Kee Wong; Athol U Wells; Daniel E Furst
Journal:  Arthritis Rheumatol       Date:  2016-02       Impact factor: 10.995

10.  Correlates and responsiveness to change of measures of skin and musculoskeletal disease in early diffuse systemic sclerosis.

Authors:  Alexandra B Wiese; Veronica J Berrocal; Daniel E Furst; James R Seibold; Peter A Merkel; Maureen D Mayes; Dinesh Khanna
Journal:  Arthritis Care Res (Hoboken)       Date:  2014-11       Impact factor: 4.794

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.